BioSpect the business of Bi
24 years of leveraging the business of Bio
www.biospectrumindia.co

Qure.ai appoints Amit Kakar, Charles-Antoine Janssen to its Board of Directors

09 May 2022 | News

The company has also added Navjeewan Khosla from Novo Holdings and Ajay Mahipal from HealthQuad as Board Observers



Qure.ai has announced the appointment of two new members to its Board of Directors. Joining the team at the helm are Dr Amit Kakar MD, from Novo Holdings and Charles-Antoine Janssen, Chief Investment Officer, HealthQuad. The company has also appointed Navjeewan Khosla, Principal, Novo Holdings and Ajay Mahipal, Director, HealthQuad, as Board Observers.

Dr Amit Kakar is Senior Partner, Head of Novo Holdings Asia, and a healthcare professional with over 30 years of experience across key verticals including medical technology, R&D, manufacturing, pharma retail, drug discovery, clinical research, biotech, hospitals and diagnostic centres, primary and specialty care centres, among others. He is currently part of the Board of Directors of Singapore-based life science company, ESCO, and telemedicine portal – Doctor Anywhere.

Charles-Antoine Janssen is the Chief Investment Officer at HealthQuad and the Co-Founder & Managing Partner at KOIS, a global impact investing firm. Janssen has over 26 years of industry experience and is a well-versed impact investor focussed on healthcare access. Janssen serves on the board of Medikabazaar, THB, Lilac Insights, TC4AI, Regency Hospitals, GoJob, the Climate School and Potential Project, and on the Advisory Board of Lighthouse (India PE fund) and Quadria (Asia healthcare PE fund).